Stanford Health Care’s menopause page is unusually specific about several nonhormonal options. It names fezolinetant and gabapentin alongside antidepressants, while also describing sleep assessment, physical therapy and other approaches. That specificity helps a reader identify the next question; it does not settle which option is suitable or what will be prescribed.
Reviewed September 29, 2026, this assessment separates the published treatment menu from the current safety information for one named medicine. It also considers the differences among hot-flash relief, sleep care and local comfort products. No treatment sequence, dose or personal monitoring plan is supplied.
Read the menu as several different clinical jobs
Stanford’s treatment page places antidepressants, fezolinetant and gabapentin under nonhormonal medications and products. It separately describes lubricants and moisturizers for temporary relief of dryness and sexual pain. Those descriptions do not make every option a treatment for every symptom.
The medicine-families guide keeps the purpose of a medicine separate from its category. At Stanford, that means asking which complaint a proposed option is meant to change and how that change would be assessed. The page confirms that these approaches belong to its discussion of care; it does not identify a patient’s selected brand, dispensing pharmacy or treatment outcome.
Fezolinetant brings a specific current warning
The current Veozah label identifies fezolinetant for moderate to severe vasomotor symptoms due to menopause and carries a boxed warning for liver toxicity. It requires liver testing before treatment and follow-up testing during treatment. Stanford’s mention of the active ingredient should therefore be read alongside this medicine-specific safety information.
The liver-monitoring context guide explains why an identified prescriber and result-review process matter. This review does not translate the label into a personal schedule. A clinic’s inclusion of a treatment in its public menu does not prove that testing has been arranged, that results permit treatment or that an individual is eligible.
Contraindications cannot be reduced to a preference against hormones
The Veozah prescribing information lists known cirrhosis, severe kidney impairment or end-stage kidney disease, and use with CYP1A2 inhibitors as contraindications. These are explicit product restrictions. They demonstrate why choosing to avoid hormones does not by itself establish suitability for fezolinetant.
The label also directs immediate discontinuation and medical attention when symptoms suggest liver injury. A clinician should explain that action and the relevant warning signs if prescribing the medicine. It is not appropriate to wait for a routine appointment when the label calls for prompt care. Neither this review nor Stanford’s general menu can resolve a person’s medicine interactions or interpret their laboratory results.
A sleep assessment answers a different kind of uncertainty
Stanford describes sleep assessments for conditions including obstructive sleep apnea and restless leg syndrome on its menopause treatment page. That is a diagnostic service, distinct from assuming that every disturbed night is caused by hot flashes. The clinic also discusses gabapentin in relation to sleep and vasomotor symptoms, but does not prescribe it to the reader through the page.
The UCLA review examines the same boundary from a broader assessment model. In both cases, naming a sleep complaint helps define the consultation; it does not establish a diagnosis or authorize a sedating medicine. Different explanations can lead to different responsibilities and different measures of improvement.
Separate comfort measures from demonstrated vasomotor benefit
Stanford includes self-care suggestions and cognitive behavioral therapy in its treatment overview. Those entries should not receive one undifferentiated evidence claim. The 2023 NAMS statement abstract recommends cognitive behavioral therapy for vasomotor symptoms, while not recommending several commonly suggested measures, including cooling techniques and trigger avoidance, as evidence-based vasomotor treatments.
The Utah review considers a broad care menu with similar evidence questions. That distinction does not deny a person’s preference for comfort. It prevents a convenient measure from being represented as an established substitute for another intervention. The statement is also dated evidence, not a complete catalogue of subsequently approved medicines. Its conclusions should be kept with the particular symptom outcome and intervention it assessed.
Access and monitoring require an operational answer
Stanford’s page describes Bay Area in-person locations and video visits. It does not establish that someone in every state can receive a remote prescription, nor does it publish a complete medicine-and-testing price. The clinical and administrative parts of access therefore need separate confirmation.
If a medicine with testing requirements is proposed, useful questions concern the ordering clinician, where results will arrive and who can act on them between visits. The Duke review illustrates how a less specific drug-family description leaves different questions open. More naming detail at Stanford improves identification; it still does not settle affordability, coverage or the division of follow-up work.
The strongest supported conclusion remains bounded
Stanford provides a documented nonhormonal treatment discussion with named options and related clinical services. That supports considering it as a care setting, not ranking it above another institution or assuming a successful prescription. The current Veozah label remains the authority for that product’s warnings rather than any shortened clinic summary.
Before treating a proposed plan as complete, the unresolved elements are the actual medicine, its purpose, eligibility assessment, cost and responsibility for follow-up. Those are questions for the clinician and service. The public menu is useful precisely when its information is retained without expanding it into a promise it does not make.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- Stanford Health Care — Menopause TreatmentsOfficial clinical service description, accessed September 29, 2026; an individual prescription, access arrangement, full price and outcome are not established. Published treatment categories are not an all-product formulary. · Checked 2026-09-29
- DailyMed — VEOZAH fezolinetant tablet, Astellas Pharma USExact oral product prescribing information, revised February 2026; boxed hepatotoxicity warning, all three contraindications and testing duties remain product-specific. Not evidence of individual clinic prescribing or a personal monitoring schedule. · Checked 2026-09-29
- The 2023 nonhormone therapy position statement of The North American Menopause Society — PubMed abstractPrimary professional position-statement abstract, published 2023; vasomotor-symptom scope only. Full article not retrieved. Predates later drug approvals; does not evaluate these clinics or equate all forms of counseling. · Checked 2026-09-29